Last reviewed · How we verify
NCT06928220: CIMMIS
The Impact of Manual Versus Mechanical Intestinal Suturing on the Incidence of Postoperative Complications Following Cystectomy With Ileal Conduit
NA trial testing cystectomy with ileal conduit, using mechanical bowel anastomosis in Bladder Cancer in 120 participants. Completed in 7 April 2025.
4 April 2025
Quick facts
| Lead sponsor | Fundacio Puigvert |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 19 October 2020 |
| Primary completion | 4 April 2025 |
| Estimated completion | 7 April 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- cystectomy with ileal conduit, using mechanical bowel anastomosis
- cystectomy with ileal conduit, using manual bowel anastomosis
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
- Anastomosis; Complications — all drugs for Anastomosis; Complications →
- Ileus Paralytic — all drugs for Ileus Paralytic →
Sponsor
Fundacio Puigvert
Who can join
18 and older, any sex, with Bladder Cancer or Anastomosis; Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Impact of Manual Versus Mechanical Intestinal Suturing on the Incidence and Management of Postoperative Complications in Patients Undergoing Radical Cystectomy with Ileal Conduit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06928220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Fundacio Puigvert trials
Trials by the same sponsor.
- NCT06866782 — European Registry of Next Generation Imaging in Advanced Prostate Cancer · recruiting
- NCT04409899 — The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department · unknown
- NCT04702347 — Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study · unknown
- NCT04712201 — En Bloc Bladder Tumor Resection: Prospective Randomized Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06928220 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacio Puigvert
- Last refreshed: 15 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06928220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing